⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNRX News
VolitionRX Limited Common Stock
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
prnewswire.com
VNRX
VolitionRx Secures $2.0 Million in Funding
prnewswire.com
VNRX
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
prnewswire.com
VNRX
Volition Issues Business Review 2025
prnewswire.com
VNRX
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
prnewswire.com
VNRX
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis USA - English France - Français
prnewswire.com
VNRX
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use USA - English France - Français
prnewswire.com
VNRX
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
prnewswire.com
VNRX
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
prnewswire.com
VNRX
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
prnewswire.com
VNRX